AeonClad Biomedical LLC
This article was originally published in Start Up
Executive Summary
AeonClad Biomedical 's AeonCoat coating technology allows for surface modification at the nanoscale or particle level. The dry, tunable coating process can precisely apply a coating as thin as a few nanometers to as thick as hundreds of microns to a medical device or a drug powder. For devices, the start-up will create lubricious coatings for easier insertion and placement, coatings to increase cell growth and adhesion, non-fouling coatings that prevent contaminants from forming, and functional coatings for convenient attachment of biological materials. For drug delivery, AeonClad is focused on improving the efficacy of poorly water soluble drugs by preventing the drug from clumping once ingested and increasing the rate at which the drug dissolves in water.
You may also be interested in...
Start-Up Previews (03/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Treating Late-Stage Prostate Cancer," features profiles of AndroBioSys, Bellicum Pharmaceuticals, Colby Pharmaceuticals and Med Discovery. Plus these Start-Ups Across Health Care: AeonClad Biomedical, Arete Therapeutics, Bonovo Orthopedics and Thrasos Therapeutics.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”